Medications for preventing osteoporosis may help lower the risk of ovarian cancer in the body

2023-08-29 19:14

EpithelialOvarian cancerThere are almost no readily modifiable risk factors. Preclinical studies suggest that bisphosphonates may have chemopreventive effects. A recent study published in the international journal JNCI: Journal of the National Cancer Institute titled 'Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older' reports that scientists from institutions including the University of Queensland have found that drugs used to prevent osteoporosis may help reduce the individual's risk of developing ovarian cancer.

Drugs used to prevent osteoporosis may help reduce the risks of ovarian cancer in the body.

In the article, researchers used de-identified medical records from 2004-2013 to study medication use among over 50,000 women aged 50 and older, analyzing differences between women who had and had not developed ovarian cancer. The researchers found that women using nitrogen-based bisphosphonate were less likely to develop ovarian cancer, but the results were different among different subtypes of ovarian cancer, including a 50% reduction in endometrial cancer risk and a 16% reduction in serous ovarian cancer risk.

Currently, researchers do not know why these drugs may lower women's risk of developing ovarian cancer, but previous studies have shown that nitrogen-based bisphosphonates may block the spread of diseased cells grown in the laboratory. Ovarian cancer is the eighth most common human cancer in Australia, with fewer than 50% of patients surviving five years after diagnosis. According to the Australian Institute of Health and Welfare, there were 1,720 new cases of ovarian cancer in 2021, with 83% of patients over 50 years old. More than 200,000 Australians are prescribed nitrogen-based bisphosphonate drugs each year, making it one of the most prescribed medications of its kind in Australia.

This medication can prevent osteoporosis and reduce the risk of fractures in patients with osteoporosis. Researchers believe that the results of this study are very important because most known ovarian cancer risk factors may not be easily changed or modified. Previous studies have shown that drugs used to treat other diseases may effectively prevent cancer, which may have led scientists to investigate bisphosphonate drugs. In the future, they will need to further research to understand why these drugs affect different subtypes of ovarian cancer patients differently. Now, researchers know that ovarian cancer subtypes look different under the microscope and have specific risk factors. However, it is important to study each subtype separately to improve understanding and awareness of these cancers.

This study may provide better drug options for patients with osteoporosis, but further research is needed to understand the mechanisms of human ovarian cancer. In conclusion, the results of this study suggest that the use of nitrogen-based bisphosphonates may be associated with a reduction in the risk of endometrial and serous ovarian cancer, revealing the potential disease prevention properties of these drugs. Of course, further research is needed to confirm these results.

Verification code:

Contact us

  • Name*

  • Email*

  • Mobile*

  • Message Description*

  • File Upload*

    upload files
    Note:Up to 1 files, each within 10M